<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494610</url>
  </required_header>
  <id_info>
    <org_study_id>114334</org_study_id>
    <nct_id>NCT01494610</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.</brief_title>
  <official_title>A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative bioavailability study to compare the pharmacokinetics and
      pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based
      inhaler versus a multi-dose dry powder inhaler in patients with moderate asthma and in
      patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

      Co-primary endpoints will be the area under the curve (AUCτ) measured for plasma Fluticasone
      propionate (pharmacokinetic) and the pharmacodynamic effects of Fluticasone propionate
      (weighted mean serum cortisol over 0-12h) on the last day of each 10 day study treatment
      period. Secondary endpoints will include the following pharmacokinetic parameters for both
      fluticasone propionate and salmeterol: AUClast, AUC(0-t), Cmax, Cmin, tmax, λz, and t1/2 as
      well as the pharmacodynamic effects of salmeterol (pulse rate, blood pressure,
      electrocardiogram [ECG], potassium and glucose) and Fluticasone propionate (urine cortisol
      levels). Safety (adverse events and laboratory abnormalities) will also be assessed as a
      secondary endpoint.

      The study is a randomised, double blind, double dummy, four-period cross-over study.
      Approximately 60 asthma or COPD patients will be randomised. Patients meeting eligibility
      criteria will receive Fluticasone propionate/salmeterol 250/50mcg bid, from a capsule-based
      inhaler and from a multi-dose dry powder inhaler for a period of 10 days each in a randomised
      order. All patients will receive treatment from each device twice. To maintain the double
      blind, each patient will receive active treatment and placebo at the same time from two
      separate devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND This study will evaluate the comparative bioavailability of SERETIDE delivered via
      the established multi-dose powder inhaler ie DISKUS/Accuhaler and a new fluticasone
      propionate/salmeterol capsule-based inhaler. Both formulations will be delivered at the
      250/50mcg (micrograms) twice daily (bid) dose strength.

      STUDY RATIONALE The fluticasone propionate/salmeterol capsule-based inhaler has been
      developed for administration in both asthma and Chronic obstructive pulmonary disease (COPD)
      patients. Therefore, both disease populations are included in this study. The study will
      assess the performance of the two devices with respect to systemic exposure and
      pharmacodynamic effects. A replicated cross-over design (four period) was chosen. This design
      reduces subject numbers by about 50% compared to a standard 2-period cross-over design.

      OBJECTIVES Primary Objective

      -To compare the performance of fluticasone propionate/salmeterol administered in a
      capsule-based inhaler with the multi-dose dry powder inhaler by evaluating fluticasone
      propionate pharmacokinetic and pharmacodynamic endpoints.

      Secondary Objectives

        -  To compare the pharmacokinetic and pharmacodynamic effects of the salmeterol component
           of fluticasone propionate/salmeterol after administration from a capsule-based inhaler
           and from the multi-dose dry powder inhaler

        -  To compare the safety and tolerability of fluticasone propionate/salmeterol after
           administration in a capsule-based inhaler with the multi-dose dry powder inhaler.

      ENDPOINTS Primary Endpoints

        -  Pharmacokinetic endpoint: AUCτ for fluticasone propionate (area under the plasma
           fluticasone propionate concentration-time curve over dosing interval) on the last day of
           each study treatment period (Day 10).

        -  Pharmacodynamic endpoint: Weighted mean serum cortisol over 12h on the last day of each
           treatment period (Day 10).

      Secondary Endpoints

        -  Pharmacokinetic parameters (AUClast, AUC(0-t), Cmax, Cmin, tmax, λz, and t1/2 for
           fluticasone propionate and salmeterol) on the last day of each treatment period (Day
           10).

        -  Pharmacodynamic parameters:

        -  Fluticasone propionate: Urine cortisol excretion (0-24h) and serum cortisol Cmin on the
           last day (Day 10) of each treatment period,

        -  Salmeterol: pharmacodynamic parameters for pulse rate, blood pressure, electrocardiogram
           (ECG), plasma potassium and glucose (weighted mean 0-12h and Cmax/Cmin) on the last day
           (Day 10) of each treatment period

        -  Safety and tolerability: Incidence of adverse events and laboratory abnormalities

      STUDY DESIGN This is a randomised, four-period cross-over, double-blind, double-dummy study.
      Patients meeting eligibility criteria will receive fluticasone propionate/salmeterol 250/50
      mcg bid from a capsule-based inhaler and from a multi-dose dry powder inhaler for 10 days per
      each treatment period in a randomised order. To maintain the double blind, each patient will
      receive both active treatment and placebo at the same time from two separate devices.
      Patients already on inhaled corticosteroid (ICS) monotherapy or combination treatment prior
      to randomization will stop their existing treatment and switch to treatment provided by the
      study-provided devices.

      The study has been designed to compare the administration of fluticasone
      propionate/salmeterol from two inhalation devices, a capsule-based inhaler and a multi-dose
      dry powder inhaler. Fluticasone propionate/salmeterol administered via the multi-dose dry
      powder inhaler will be the reference product. Fluticasone propionate/salmeterol is being
      developed by GlaxoSmithKline (GSK) as a capsule-based inhaler for administration for the
      treatment of both asthma and COPD.

      TREATMENT ASSIGNMENT Subjects will be assigned to one of two treatment sequences in
      accordance with the randomisation schedule Sequence ABBA (Periods 1 to 4): A: Fluticasone
      propionate/salmeterol from a multi-dose dry powder inhaler; B: Fluticasone
      propionate/salmeterol from a capsule-based inhaler; B: Fluticasone propionate/salmeterol from
      a capsule-based inhaler; A: Fluticasone propionate/salmeterol from a multi-dose dry powder
      inhaler Sequence BAAB (Periods 1 to 4): B: Fluticasone propionate/salmeterol from a
      capsule-based inhaler; A: Fluticasone propionate/salmeterol from a multi-dose dry powder
      inhaler; A: Fluticasone propionate/salmeterol from a multi-dose dry powder inhaler; B:
      Fluticasone propionate/salmeterol from a capsule-based inhaler.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2010</start_date>
  <completion_date type="Actual">June 8, 2011</completion_date>
  <primary_completion_date type="Actual">June 8, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted Mean Serum Cortisol (SC) Over 0 to 12 Hours Post Dose</measure>
    <time_frame>At pre-morning dose; 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body's ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma AUC(0-tau) and Plasma AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-tlast]) for Salmeterol</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tau) and AUC(0-tlast). AUC(0-tau) is a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC(0-tlast) for FP</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tlast). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of FP</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of FP in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Terminal Phase Half-life (t1/2) for FP</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for evaluating t1/2. The t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) for FP</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) for Salmeterol</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of Salmeterol in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Terminal Phase Half-life (t1/2) for Salmeterol</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for evaluating t1/2. t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Salmeterol</measure>
    <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Urine Cortisol Excretion Over 0 to 24 Hours Post Dose for FP</measure>
    <time_frame>0-24 hours post dose on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Urine samples of participants were collected to evaluate urine cortisol excretion over 0-24 hours post treatment dose. A 24-hour urine cortisol sample was used to measure the total amount of cortisol excreted in urine in 24 hours. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in the amount of cortisol excreted in the urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cortisol Minimum (Cmin) for FP</measure>
    <time_frame>Day 10 of each study period (Periods 1-4); Study Day 10 (+/-1) (reference day is Study Day 1 or Randomization day), Period 1; Study Day 20 (+/-1), Period 2; Study Day 30 (+/-1), Period 3; Study Day 40 (+/-1), Period 4</time_frame>
    <description>Blood samples of participants were collected for the evaluation of minimum serum cortisol. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in serum cortisol concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean Over 0 to 4 Hours Post Dose of Heart Rate for Salmeterol</measure>
    <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>The heart rate (number of heartbeats per unit of time, typically expressed as beats per minute [bpm]) of the participants was monitored for evaluating the weighted mean over the course of 0 to 4 hours post dose. The Capsule-MDPI difference for heart rate was calculated for each participant, and the weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. The weighted mean was calculated by using all values at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Heart Rate Over 0 to 4 Hours Post Dose for Salmeterol</measure>
    <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>The maximum observed value of heart rate was measured from the time of the morning dose on Day 10 to 4 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Diastolic Blood Pressure (DBP), Maximum Systolic Blood Pressure (SBP), and Weighted Mean for DBP and SBP Over 0 to 4 Hours Post Dose</measure>
    <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>The diastolic and systolic blood pressure of the participants was measured. The maximum and minimum observed values from the time of the morning dose on Day 10 to 4 hours post dose were measured for SBP and DBP. The weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. Weighted mean was calculated by using all values of DBP and SBP at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and Weighted Mean Over 0 to 4 Hours Post Dose of the QT Interval Corrected According to Bazett's Formula (QTc[B]) and the QT Interval Corrected According to Fridericia's Formula (QTc[F])</measure>
    <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 3 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>The electrocardiogram (ECG) of the participants was taken, and the maximum and weighted mean of QTc(B) and QTc(F) was measured. Weighted mean was calculated by using all values of QTc(B) and QTc(F) at the indicated timepoint contributing to the calculation of the mean but with different weightage. The ECG helps in the assessment of the condition of the heart. The QT interval gives the measure of the heart rate, and the cQT interval gives the corrected value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean Over 0 to 4 Hours Post Dose of Plasma Potassium and Minimum (Min) Plasma Potassium</measure>
    <time_frame>At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the minimum plasma potassium level. Weighted mean was calculated by using all values of plasma potassium at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean Over 0 to 4 Hours Post Dose and Maximum Plasma Glucose</measure>
    <time_frame>At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the maximum plasma glucose level. Weighted mean was calculated by using all values of plasma glucose at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell (WBC) Count</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and WBC count. Data are reported for the first (1st) and second (2nd) administration (admin) of FP/salmeterol via MDPI or capsule-based inhaler. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hemoglobin and Mean Corpuscular Hemoglobin (MCH) Concentration</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of mean hemoglobin (mean level of hemoglobin in the whole blood sample) and MCH concentration. The MCH concentration is the average concentration of hemoglobin in a red blood cell. Hemoglobin is the red pigment in the blood, and it is reponsible for carrying oxygen. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) Count and Reticulocytes</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of RBC and reticulocytes count. Reticulocytes are immature red blood cells. Normally, about 1% to 2% of the red blood cells in the blood are reticulocytes. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscule Hemoglobin (MCH)</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of MCH. MCH is the average mass or amount of hemoglobin per red blood cell in a sample of blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscle Volume (MCV)</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of MCV. MCV is a measure of the average red blood cell size that is reported as part of a standard complete blood count. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hematocrit</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of hematocrit. The hematocrit is the percentage of the RBCs in the blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Albumin and Total Protein</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST), and Gama Glutamyl Transferase (GGT)</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of AP, ALT, AST, and GGT. All of these parameters are measured to help assess the condition of the liver. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Direct Bilirubin (DB), Total Bilirubin (TB), Creatinine, and Uric Acid</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of DP, TB, creatinine, and uric acid. DB and TB are measures that help assess the condition of the liver, and creatinine and uric acid are measures that help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Calcium, Chloride, Glucose, Potassium, Sodium, Carbon Dioxide (CO2) Content/Bicarbonate (Bicar), and Urea/Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
    <description>Blood samples of participants were collected for the evaluation of calcium, chloride, glucose, potassium, sodium, carbon dioxide (CO2) content/bicarbonate, and urea/BUN. All of these parameters are measured to help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Adverse Event (AE)</measure>
    <time_frame>Randomization (Day 1) up to Follow-up (Days 47-50)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SERETIDE Rotacaps</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SERETIDE Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Rotacaps</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered in a capsule-based inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Diskus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered in a multi-dose dry powder inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SERETIDE Rotacaps</intervention_name>
    <description>The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.</description>
    <arm_group_label>Placebo Diskus</arm_group_label>
    <arm_group_label>SERETIDE Rotacaps</arm_group_label>
    <other_name>Placebo delivered via a capsule-based inhaler</other_name>
    <other_name>Physical examination</other_name>
    <other_name>adverse event (AE) and serious AE assessments</other_name>
    <other_name>clinical laboratory safety tests (blood and urine)</other_name>
    <other_name>12-lead electrocardiogram assessment</other_name>
    <other_name>SERETIDE delivered via a capsule-based inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SERETIDE Diskus</intervention_name>
    <description>The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.</description>
    <arm_group_label>Placebo Rotacaps</arm_group_label>
    <arm_group_label>SERETIDE Diskus</arm_group_label>
    <other_name>Physical examination</other_name>
    <other_name>adverse event (AE) and serious AE assessments</other_name>
    <other_name>clinical laboratory safety tests (blood and urine)</other_name>
    <other_name>12-lead electrocardiogram assessment</other_name>
    <other_name>SERETIDE delivered via a multi-dose dry powder inhaler</other_name>
    <other_name>Placebo delivered via a multi-dose dry powder inhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        ALL PATIENTS:

          -  Available for the duration of the study and able to attend the clinic for all study
             visits.

          -  Gender: male or female

        A female subject is eligible to participate if she is of:

          -  Non-childbearing potential defined as pre-menopausal females with a documented tubal
             ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous
             amenorrhea [in questionable cases a blood sample with simultaneous follicle
             stimulating hormone (FSH) &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) is
             confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal
             status is in doubt will be required to use one of the protocol allowed contraception
             methods if they wish to continue their HRT during the study. Otherwise, they must
             discontinue HRT to allow confirmation of post-menopausal status prior to study
             enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the
             cessation of therapy and the blood draw; this interval depends on the type and dosage
             of HRT. Following confirmation of their post-menopausal status, they can resume use of
             HRT during the study without use of a contraceptive method.

          -  Child-bearing potential and agrees to use one of the protocol allowed contraception
             methods for an appropriate period of time (as determined by the product label or
             investigator) prior to the start of dosing to sufficiently minimize the risk of
             pregnancy at that point. Female subjects must agree to use contraception until they
             have attended the site for the follow-up visit.

          -  Capable of giving informed consent, which includes compliance with the study
             requirements and restrictions listed in the consent form.

          -  Body mass index between 18 and 35 kg/m2 inclusive at Screening

          -  Able to use the inhaler devices adequately after training

          -  AST and ALT &lt; 2xULN (upper limit of normal); alkaline phosphatase and bilirubin less
             than or equal to 1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt;35%).

          -  QT interval corrected for heart rate (QTc)* &lt;450 millisecond (msec)** QTc &lt;480 msec
             for patients with bundle branch block

               -  either QTcB (QTc Bazzett's formula) or QTcF (QTc Fridericia's formula), machine
                  or manual overread, males or females. The specific formula that will be used in a
                  study should be predetermined prior to the initiation of the study. The QT
                  correction formula used to determine inclusion and discontinuation should be the
                  same throughout the study.

                    -  based on single or averaged QTc values of triplicate ECGs obtained over a
                       brief recording period

        COPD PATIENTS:

          -  Diagnosis: COPD patients, defined as either Stage III to Stage IV COPD diagnosis
             according to GOLD criteria (Global Strategy for the Diagnosis, Management, and
             Prevention of COPD, updated 2009) [GOLD, 2009]. Individuals must be otherwise healthy
             individuals who are free from significant cardiac, gastrointestinal, hepatic, renal,
             haematological malignancy, endocrine, neurological and psychiatric disease as
             determined by history, physical examination and screening investigations.

          -  Age: 40-80 years inclusive at the time of signing the informed consent.

          -  Post-bronchodilator forced expiratory volume in one second (FEV1) &lt; 50% of predicted
             normal values at Screening. Patients must abstain from short acting beta agonist
             (SABA) use for 6 hours prior to the screening visit.

          -  Post-bronchodilator FEV1/FVC ratio ≤ 0.70 at Screening

          -  An increase of less than 15% from baseline FEV1 or an absolute change of &lt; 200ml, 30
             minutes after inhalation of 400mcg of salbutamol by metered-dose inhaler (MDI) and
             spacer or 2.5mg by nebuliser at Screening.

          -  Ex smokers for at least the past 3 months with a pack history ≥10 pack years [number
             of pack years = (number of cigarettes per day / 20) x number of years smoked].

          -  COPD therapy:

          -  Patients on fluticasone propionate/salmeterol combination 250/50mcg bid via a
             multi-dose dry powder inhaler prior to the study will be allowed to remain on their
             treatment regimen until randomization provided all other eligibility criteria are met.

          -  Patients on fluticasone propionate/salmeterol combination 250/50mcg bid via a metered
             dose inhaler or the equivalent dose of budesonide/formoterol, 800/24mcg (total daily
             dose) via a turbuhaler will be switched to fluticasone propionate/salmeterol
             combination 250/50mcg bid via the GSK provided multi-dose dry powder inhaler for
             between 14 and 28 days prior to randomization.

          -  Patients on tiotropium in addition to ICS/LABA (long-acting beta agonist) treatment
             (up to a total daily dose of 500mcg fluticasone propionate or other ICS equivalent eg.
             800mcg budesonide) may continue their tiotropium treatment throughout the study.

          -  Patients on tiotropium monotherapy will need to start treatment with fluticasone
             propionate/salmeterol combination 250/50mcg bid via the GSK provided multi-dose dry
             powder inhaler for between 14 and 28 days prior to randomization. They may continue
             their tiotropium treatment throughout the study.

          -  Patients on LABA therapy (eg. salmeterol 50mcg) will need to start treatment with
             fluticasone propionate/salmeterol combination 250/50mcg bid via the GSK provided
             multi-dose dry powder inhaler for between 14 and 28 days prior to randomization.

        ASTHMA PATIENTS:

          -  Diagnosis: Patients with moderate asthma as defined by the Global Initiative for
             Asthma (GINA) guidelines at Screening. A best FEV1 of 60-85% of the predicted normal
             value at the Screening visit. NHANES (National Health and Nutrition Examination
             Survey) III predicted values will be used [Hankinson, 2009]. If a subject is recorded
             as having Hispanic or Latino ethnicity, then the Mexican-American equations will be
             used (irrespective of race). If a subject is recorded as being of African
             American/African Heritage race, then the African American equations will be used. If a
             subject is recorded as being of Asian or of Pacific Islander race, then the Caucasian
             formula will be used with a conversion factor of 0.88. Otherwise, the Caucasian
             equations will be used.

          -  Age: 18 and above at the time of signing the informed consent.

          -  Best clinic screening pre-bronchodilator FEV1 between 60 and 85% of predicted normal
             values (NHANES III values). Patients must abstain from SABA use for 6 hours prior to
             the Screening visit.

          -  Asthma therapy:

          -  Patients on fluticasone propionate/salmeterol combination 250/50mcg treatment via a
             multi-dose dry powder inhaler prior to the study will be allowed to remain on their
             treatment regimen until randomization provided all other eligibility criteria are met.

          -  Patients on treatment with ICS alone (up to a total daily dose of 500mcg fluticasone
             propionate or other ICS equivalent eg. 800mcg budesonide) will be required to switch
             treatment to fluticasone propionate/salmeterol combination 250/50mcg bid via the GSK
             provided multi-dose powder inhaler for between 14 and 28 days prior to randomization
             if deemed appropriate.

          -  Patients on treatment with budesonide/eformoterol combination (up to a total daily
             dose of 800/24mcg via a Turbuhaler) will be required to switch to fluticasone
             propionate/salmeterol combination 250/50mcg bid via the GSK-provided multi-dose powder
             inhaler for between 14 and 28 days prior to randomization.

          -  Patients on treatment with fluticasone propionate/salmeterol combination at a dose up
             to 250/50mcg bid via a metered dose inhaler or multi-dose dry powder inhaler (eg.
             100/50mcg) will be required to switch to fluticasone propionate/salmeterol combination
             250/50mcg bid via the GSK-provided multi-dose powder inhaler for between 14 and 28
             days prior to randomization.

        EXCLUSION CRITERIA:

        ALL PATIENTS:

          -  Any clinically relevant medical condition or abnormality identified during the
             screening medical assessment and procedures, physical examination, or laboratory
             assessments (including clinical chemistry and haematology), which in the opinion of
             the GSK Medical Monitor is likely to affect the safety of the subject and/or interfere
             with the study procedures and outcomes.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody or
             positive HIV test result within 3 months of screening.

          -  Patients on treatment with fluticasone propionate either as monotherapy or in
             combination at a total daily dose higher than 500mcg or budesonide monotherapy or in
             combination at a total daily dose higher than 800mcg are excluded from the study

          -  Use of oral/injectable/depot corticosteroid for any indication within 3 months prior
             to the Screening visit.

          -  Use of intra-nasal steroids (INS). To be eligible for the study, patients on INS
             therapy will be required to switch to non-INS therapy at randomization.

          -  Patients with abnormal levels of serum cortisol at Screening

          -  Abuse of alcohol consumption within 12 months of the Screening visit defined by the
             following Australian guidelines:

        Males: An average weekly intake greater than 21 units or an average daily intake greater
        than 3 units. Females: An average weekly intake greater than 14 units or an average daily
        intake greater than 2 units.

        One unit is equivalent to 270 mL of full strength beer, 470 mL of light beer, 30 mL of
        spirits and 100 mL of wine.

          -  A known or suspected history of drug abuse within 12 months of the Screening visit.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500mL within a 56-day period.

          -  Known hypersensitivity to salbutamol or any ingredient in the study medication
             preparation and/or history of any other drug or other allergy that, in the opinion of
             the GSK medical monitor and the investigator contraindicates participation of the
             subject

          -  Grapefruit or grapefruit juice containing products are excluded from 2 weeks prior to
             randomisation until collection of the final blood sample at treatment period 4.

          -  Drugs that inhibit the cytochrome P450 isoform, 3A4 (CYP3A4), are excluded from 2
             weeks prior to randomisation until collection of the final blood sample at treatment
             period 4. CYP3A4 inhibitors include cimetidine, clarithromycin, erythromycin,
             ciprofloxacin, ritonavir, ketoconazole, and azole antifungals, a complete list is
             provided in the protocol.

          -  Use of prescription or non-prescription drugs, vitamins, herbal and dietary
             supplements, within seven days or 5 half-lives (whichever is longer) prior to the
             first dose of study medication, which in the opinion of the Principal Investigator,
             may interfere with study outcome. Specifically, calcium and vitamin D supplements and
             bisphosphonates are not allowed throughout the study.

          -  Pregnant females as determined by positive serum or urine βhCG (β-human chorionic
             gonadotropin) test at Screening or prior to dosing.

          -  Patients, who, in the opinion of the Investigator, are not able to comply with the
             protocol requirements.

        COPD PATIENTS:

          -  Subjects with a respiratory disorder in addition to COPD (e.g. bronchiectasis,
             fibrosis) or significant co-morbidity that might affect lung function (e.g. poorly
             controlled heart failure, atrial fibrillation or ischaemic heart disease).

          -  Regular oxygen or nebulised bronchodilator therapy

          -  The subject has history of a respiratory infection (including sinusitis) within 4
             weeks prior to the Screening visit

          -  Any previous lung resection surgery (eg., lung volume reduction surgery or lobectomy)

        ASTHMA PATIENTS:

          -  Acute exacerbation of asthma requiring hospitalisation in the 6 weeks prior to the
             Screening visit.

          -  Subjects may not have used inhaled tobacco products within the past 3 months (ie.
             cigarettes, cigars or pipe tobacco) or have historical use of 10 pack years or more;
             [number of pack years = (number of cigarettes per day / 20) x number of years smoked].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Former Glaxo Wellcome study RPS10001/SFCF1001: A Phase I, monocentric, randomised, double-blind, double dummy, cross-over study to compare the pharmacokinetics and pharmacodynamic effects of Seretide 50µg/250µg bid after repeat dosing, delivered by GSK's multi-dose dry powder inhaler™ versus RPID in patients with moderate asthma; [GW Document number PM1998/00015/00].</citation>
  </reference>
  <reference>
    <citation>GINA: Global strategy for asthma management and prevention. NHLBI/WHO/GARD, Washingon DC 2006-updated 2009.</citation>
  </reference>
  <reference>
    <citation>GlaxoSmithKline Document Number RM2002/00280/01. CCI18781 Investigator's Brochure, dated 22 Aug 2006</citation>
  </reference>
  <reference>
    <citation>GlaxoSmithKline Document Number RM2007/00413/01. CCI18781+GR33343 Investigator's Brochure, version number 10, dated 26 Mar 2009.</citation>
  </reference>
  <reference>
    <citation>GlaxoSmithKline study SAS10006: A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of Fluticasone propionate (FP) administered twice daily via the GSK'S MULTI-DOSE DRY POWDER INHALER® (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the GSK'S MULTI-DOSE DRY POWDER INHALER; [GSK Document number RM2002/00219/00].</citation>
  </reference>
  <reference>
    <citation>Fabbri L, Pauwels RA, Hurd SS; GOLD Scientific Committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. COPD. 2004 Apr;1(1):105-41; discussion 103-4.</citation>
    <PMID>16997745</PMID>
  </reference>
  <reference>
    <citation>Patterson S, Jones B. 2006. Bioequivalence and statistics in clinical pharmacology. Chapman &amp; Hall/CRC.</citation>
  </reference>
  <reference>
    <citation>Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008 Oct-Dec;7(4):245-62.</citation>
    <PMID>17710740</PMID>
  </reference>
  <reference>
    <citation>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.</citation>
    <PMID>3450848</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <results_first_submitted>February 16, 2012</results_first_submitted>
  <results_first_submitted_qc>April 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2012</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>replicated cross-over design</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>Fluticasone propionate/Salmeterol</keyword>
  <keyword>capsule-based inhaler</keyword>
  <keyword>COPD</keyword>
  <keyword>asthma</keyword>
  <keyword>multi dose dry powder inhaler</keyword>
  <keyword>bioavailability</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114334</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FP/Salmeterol 250/50 mcg: Sequence ABBA</title>
          <description>Participants received fluticasone propionate (FP)/salmeterol 250/50 micrograms (mcg) twice daily via a capsule-based inhaler for two 10-day periods and via a multi-dose dry powder (MDPI) inhaler for two 10-day periods in a replicate crossover design. Participants were dosed approximately every 12 hours. Treatment was given in the sequence of ABBA in Periods 1, 2, 3, and 4 (with no washouts between periods), respectively. A, FP/salmeterol from an MDPI; B, FP/salmeterol from a capsule-based inhaler.</description>
        </group>
        <group group_id="P2">
          <title>FP/Salmeterol 250/50 mcg: Sequence BAAB</title>
          <description>Participants received fluticasone propionate (FP)/salmeterol 250/50 micrograms (mcg) twice daily via a capsule-based inhaler for two 10-day periods and via a multi-dose dry powder (MDPI) inhaler for two 10-day periods in a replicate crossover design. Participants were dosed approximately every 12 hours. Treatment was given in the sequence of BAAB in Periods 1, 2, 3, and 4 (with no washouts between periods), respectively. A, FP/salmeterol from an MDPI; B, FP/salmeterol from a capsule-based inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FP/Salmeterol 250/50 mcg</title>
          <description>Participants received fluticasone propionate (FP)/salmeterol 250/50 micrograms (mcg) twice daily via a capsule-based inhaler for two 10-day periods and via a multi-dose dry powder (MDPI) inhaler for two 10-day periods in a replicate crossover design. Participants were dosed approximately every 12 hours. Treatment was given in one of two sequences in Periods 1, 2, 3, and 4 (with no washouts between periods), respectively: ABBA, BAAB. A, FP/salmeterol from an MDPI; B, FP/salmeterol from a capsule-based inhaler.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="18.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White-White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP</title>
        <description>Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>Pharmacokinetic/pharmacodynamic (PK/PD) Population: all participants who received at least one dose of study medication, except for one who was identified as a full protocol violator. Participants with at least one non-missing value in the replicate observations were included.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP</title>
          <description>Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing.</description>
          <population>Pharmacokinetic/pharmacodynamic (PK/PD) Population: all participants who received at least one dose of study medication, except for one who was identified as a full protocol violator. Participants with at least one non-missing value in the replicate observations were included.</population>
          <units>Picogram hours per milliliter (pg*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.9" lower_limit="337.0" upper_limit="421.6"/>
                    <measurement group_id="O2" value="573.1" lower_limit="519.3" upper_limit="632.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350.5" lower_limit="296.5" upper_limit="414.4"/>
                    <measurement group_id="O2" value="559.1" lower_limit="490.1" upper_limit="637.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.4" lower_limit="363.1" upper_limit="477.6"/>
                    <measurement group_id="O2" value="593.0" lower_limit="505.7" upper_limit="695.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. A two one-sided t-test procedure with α=0.05 for each one-sided test was used. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.508</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.366</ci_lower_limit>
            <ci_upper_limit>1.665</ci_upper_limit>
            <estimate_desc>Data reflect Asthma + COPD participants. The ratio of adjusted geometric means is a comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.598</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.369</ci_lower_limit>
            <ci_upper_limit>1.864</ci_upper_limit>
            <estimate_desc>Data reflect participants with asthma only. The ratio of adjusted geometric means is a comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. A two one-sided t-test procedure with α=0.05 for each one-sided test was used. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>1.421</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.274</ci_lower_limit>
            <ci_upper_limit>1.584</ci_upper_limit>
            <estimate_desc>Data reflect participants with COPD only. The ratio of adjusted geometric means is the comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weighted Mean Serum Cortisol (SC) Over 0 to 12 Hours Post Dose</title>
        <description>Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body’s ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval.</description>
        <time_frame>At pre-morning dose; 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean Serum Cortisol (SC) Over 0 to 12 Hours Post Dose</title>
          <description>Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body’s ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval.</description>
          <population>PK/PD Population</population>
          <units>Nanomoles per liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD;n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.5" lower_limit="178.7" upper_limit="209.6"/>
                    <measurement group_id="O2" value="178.3" lower_limit="164.2" upper_limit="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.3" lower_limit="169.1" upper_limit="207.6"/>
                    <measurement group_id="O2" value="166.6" lower_limit="150.4" upper_limit="184.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.4" lower_limit="177.0" upper_limit="231.4"/>
                    <measurement group_id="O2" value="195.6" lower_limit="171.1" upper_limit="223.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. A two one-sided t-test procedure with α=0.05 for each one-sided test was used. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.928</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.886</ci_lower_limit>
            <ci_upper_limit>0.971</ci_upper_limit>
            <estimate_desc>Data reflect Asthma + COPD participants. The ratio of adjusted geometric means is the comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. A two one-sided t-test procedure with α=0.05 for each one-sided test was used. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.892</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.848</ci_lower_limit>
            <ci_upper_limit>0.939</ci_upper_limit>
            <estimate_desc>Data reflect participants with asthma only. The ratio of adjusted geometric means is the comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of within-par. coefficient of variation for AUC(0-tau) of FP and weighted mean (0-12 h) serum cortisol from previous studies showed that a sample size of 52 par. would have approximately 90% power to demonstrate biocomparability with respect to the two co-primary endpoints. The study was powered on the analysis of asthma and COPD par. as a combined group. A two one-sided t-test procedure with α=0.05 for each one-sided test was used. Biocomparability limits of 0.8 and 1.25 were used.</non_inferiority_desc>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>0.966</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.889</ci_lower_limit>
            <ci_upper_limit>1.049</ci_upper_limit>
            <estimate_desc>Data reflect participants with COPD only. The ratio of adjusted geometric means is the comparision of treatment administered by the capsule-based inhaler and the MDPI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma AUC(0-tau) and Plasma AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-tlast]) for Salmeterol</title>
        <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tau) and AUC(0-tlast). AUC(0-tau) is a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma AUC(0-tau) and Plasma AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-tlast]) for Salmeterol</title>
          <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tau) and AUC(0-tlast). AUC(0-tau) is a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
          <population>PK/PD Population</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-tau), asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.2" lower_limit="273.0" upper_limit="330.1"/>
                    <measurement group_id="O2" value="345.1" lower_limit="310.8" upper_limit="383.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tau), asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.8" lower_limit="274.6" upper_limit="340.6"/>
                    <measurement group_id="O2" value="356.4" lower_limit="315.4" upper_limit="402.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tau), COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.7" lower_limit="244.4" upper_limit="350.5"/>
                    <measurement group_id="O2" value="330.1" lower_limit="272.1" upper_limit="400.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t), asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.5" lower_limit="277.7" upper_limit="331.7"/>
                    <measurement group_id="O2" value="345.0" lower_limit="310.7" upper_limit="383.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t), asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.2" lower_limit="273.9" upper_limit="340.2"/>
                    <measurement group_id="O2" value="356.4" lower_limit="315.3" upper_limit="402.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t), COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.2" lower_limit="256.9" upper_limit="353.2"/>
                    <measurement group_id="O2" value="330.0" lower_limit="272.0" upper_limit="400.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AUC(0-tlast) for FP</title>
        <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tlast). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AUC(0-tlast) for FP</title>
          <description>Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tlast). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration.</description>
          <population>PK/PD Population</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.1" lower_limit="342.7" upper_limit="421.6"/>
                    <measurement group_id="O2" value="580.9" lower_limit="530.2" upper_limit="636.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.7" lower_limit="306.0" upper_limit="413.4"/>
                    <measurement group_id="O2" value="558.4" lower_limit="489.6" upper_limit="636.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.5" lower_limit="363.2" upper_limit="477.6"/>
                    <measurement group_id="O2" value="613.2" lower_limit="539.9" upper_limit="696.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of FP</title>
        <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of FP in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum, respectively.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of FP</title>
          <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of FP in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum, respectively.</description>
          <population>PK/PD Population</population>
          <units>Picograms per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Asthma + COPD; n= 57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.64" lower_limit="49.70" upper_limit="60.08"/>
                    <measurement group_id="O2" value="105.79" lower_limit="95.70" upper_limit="116.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.66" lower_limit="47.36" upper_limit="60.80"/>
                    <measurement group_id="O2" value="109.98" lower_limit="95.79" upper_limit="126.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.02" lower_limit="47.91" upper_limit="65.50"/>
                    <measurement group_id="O2" value="100.29" lower_limit="86.06" upper_limit="116.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.904" lower_limit="14.025" upper_limit="18.035"/>
                    <measurement group_id="O2" value="21.547" lower_limit="19.198" upper_limit="24.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.635" lower_limit="11.448" upper_limit="16.239"/>
                    <measurement group_id="O2" value="18.866" lower_limit="15.979" upper_limit="22.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.654" lower_limit="16.898" upper_limit="22.859"/>
                    <measurement group_id="O2" value="25.866" lower_limit="22.703" upper_limit="29.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Terminal Phase Half-life (t1/2) for FP</title>
        <description>Blood samples of participants were collected for evaluating t1/2. The t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Terminal Phase Half-life (t1/2) for FP</title>
          <description>Blood samples of participants were collected for evaluating t1/2. The t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
          <population>PK/PD Population. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.660" lower_limit="6.164" upper_limit="7.197"/>
                    <measurement group_id="O2" value="5.844" lower_limit="5.416" upper_limit="6.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.906" lower_limit="5.402" upper_limit="6.458"/>
                    <measurement group_id="O2" value="5.238" lower_limit="4.789" upper_limit="5.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.740" lower_limit="6.915" upper_limit="8.663"/>
                    <measurement group_id="O2" value="6.806" lower_limit="6.089" upper_limit="7.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) for FP</title>
        <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) for FP</title>
          <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
          <population>PK/PD Population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" lower_limit="0.08" upper_limit="5.00"/>
                    <measurement group_id="O2" value="0.530" lower_limit="0.08" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.08" upper_limit="4.04"/>
                    <measurement group_id="O2" value="0.335" lower_limit="0.08" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.173" lower_limit="0.17" upper_limit="5.00"/>
                    <measurement group_id="O2" value="0.673" lower_limit="0.13" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) for Salmeterol</title>
        <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of Salmeterol in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) for Salmeterol</title>
          <description>Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of Salmeterol in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum.</description>
          <population>PK/PD Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.28" lower_limit="53.45" upper_limit="65.74"/>
                    <measurement group_id="O2" value="92.27" lower_limit="80.52" upper_limit="105.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.97" lower_limit="56.53" upper_limit="74.66"/>
                    <measurement group_id="O2" value="110.21" lower_limit="94.76" upper_limit="128.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.26" lower_limit="44.94" upper_limit="60.77"/>
                    <measurement group_id="O2" value="72.27" lower_limit="57.75" upper_limit="90.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.752" lower_limit="11.504" upper_limit="14.134"/>
                    <measurement group_id="O2" value="14.354" lower_limit="12.859" upper_limit="16.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.676" lower_limit="11.097" upper_limit="14.479"/>
                    <measurement group_id="O2" value="14.634" lower_limit="12.806" upper_limit="16.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.857" lower_limit="10.798" upper_limit="15.307"/>
                    <measurement group_id="O2" value="13.978" lower_limit="11.464" upper_limit="17.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Terminal Phase Half-life (t1/2) for Salmeterol</title>
        <description>Blood samples of participants were collected for evaluating t1/2. t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Terminal Phase Half-life (t1/2) for Salmeterol</title>
          <description>Blood samples of participants were collected for evaluating t1/2. t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached.</description>
          <population>PK/PD Population. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.576" lower_limit="6.080" upper_limit="7.112"/>
                    <measurement group_id="O2" value="7.260" lower_limit="6.792" upper_limit="7.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=32, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.429" lower_limit="6.021" upper_limit="6.865"/>
                    <measurement group_id="O2" value="7.538" lower_limit="6.840" upper_limit="8.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.776" lower_limit="5.727" upper_limit="8.018"/>
                    <measurement group_id="O2" value="6.905" lower_limit="6.309" upper_limit="7.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for Salmeterol</title>
        <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
        <time_frame>At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Salmeterol</title>
          <description>Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug.</description>
          <population>PK/PD Population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.08" upper_limit="6.50"/>
                    <measurement group_id="O2" value="0.080" lower_limit="0.08" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.335" lower_limit="0.08" upper_limit="6.50"/>
                    <measurement group_id="O2" value="0.080" lower_limit="0.08" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.08" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.080" lower_limit="0.08" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Urine Cortisol Excretion Over 0 to 24 Hours Post Dose for FP</title>
        <description>Urine samples of participants were collected to evaluate urine cortisol excretion over 0-24 hours post treatment dose. A 24-hour urine cortisol sample was used to measure the total amount of cortisol excreted in urine in 24 hours. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in the amount of cortisol excreted in the urine.</description>
        <time_frame>0-24 hours post dose on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Urine Cortisol Excretion Over 0 to 24 Hours Post Dose for FP</title>
          <description>Urine samples of participants were collected to evaluate urine cortisol excretion over 0-24 hours post treatment dose. A 24-hour urine cortisol sample was used to measure the total amount of cortisol excreted in urine in 24 hours. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in the amount of cortisol excreted in the urine.</description>
          <population>PK/PD Population</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.53" lower_limit="56.71" upper_limit="71.17"/>
                    <measurement group_id="O2" value="59.66" lower_limit="51.45" upper_limit="69.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.86" lower_limit="62.97" upper_limit="84.32"/>
                    <measurement group_id="O2" value="66.28" lower_limit="55.25" upper_limit="79.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.62" lower_limit="44.77" upper_limit="61.83"/>
                    <measurement group_id="O2" value="51.62" lower_limit="40.16" upper_limit="66.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cortisol Minimum (Cmin) for FP</title>
        <description>Blood samples of participants were collected for the evaluation of minimum serum cortisol. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in serum cortisol concentrations.</description>
        <time_frame>Day 10 of each study period (Periods 1-4); Study Day 10 (+/-1) (reference day is Study Day 1 or Randomization day), Period 1; Study Day 20 (+/-1), Period 2; Study Day 30 (+/-1), Period 3; Study Day 40 (+/-1), Period 4</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cortisol Minimum (Cmin) for FP</title>
          <description>Blood samples of participants were collected for the evaluation of minimum serum cortisol. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in serum cortisol concentrations.</description>
          <population>PK/PD Population</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="77.9" upper_limit="100.8"/>
                    <measurement group_id="O2" value="79.6" lower_limit="69.0" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="67.0" upper_limit="95.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="57.8" upper_limit="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" lower_limit="85.0" upper_limit="123.3"/>
                    <measurement group_id="O2" value="94.9" lower_limit="77.1" upper_limit="116.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean Over 0 to 4 Hours Post Dose of Heart Rate for Salmeterol</title>
        <description>The heart rate (number of heartbeats per unit of time, typically expressed as beats per minute [bpm]) of the participants was monitored for evaluating the weighted mean over the course of 0 to 4 hours post dose. The Capsule-MDPI difference for heart rate was calculated for each participant, and the weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. The weighted mean was calculated by using all values at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
        <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean Over 0 to 4 Hours Post Dose of Heart Rate for Salmeterol</title>
          <description>The heart rate (number of heartbeats per unit of time, typically expressed as beats per minute [bpm]) of the participants was monitored for evaluating the weighted mean over the course of 0 to 4 hours post dose. The Capsule-MDPI difference for heart rate was calculated for each participant, and the weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. The weighted mean was calculated by using all values at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
          <population>PK/PD Population</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" spread="8.66"/>
                    <measurement group_id="O2" value="66.7" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="8.99"/>
                    <measurement group_id="O2" value="65.7" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="7.96"/>
                    <measurement group_id="O2" value="68.1" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Maximum Heart Rate Over 0 to 4 Hours Post Dose for Salmeterol</title>
        <description>The maximum observed value of heart rate was measured from the time of the morning dose on Day 10 to 4 hours post dose.</description>
        <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Maximum Heart Rate Over 0 to 4 Hours Post Dose for Salmeterol</title>
          <description>The maximum observed value of heart rate was measured from the time of the morning dose on Day 10 to 4 hours post dose.</description>
          <population>PK/PD Population</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="9.86"/>
                    <measurement group_id="O2" value="74.3" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="10.52"/>
                    <measurement group_id="O2" value="73.5" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="8.98"/>
                    <measurement group_id="O2" value="75.4" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Diastolic Blood Pressure (DBP), Maximum Systolic Blood Pressure (SBP), and Weighted Mean for DBP and SBP Over 0 to 4 Hours Post Dose</title>
        <description>The diastolic and systolic blood pressure of the participants was measured. The maximum and minimum observed values from the time of the morning dose on Day 10 to 4 hours post dose were measured for SBP and DBP. The weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. Weighted mean was calculated by using all values of DBP and SBP at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
        <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Diastolic Blood Pressure (DBP), Maximum Systolic Blood Pressure (SBP), and Weighted Mean for DBP and SBP Over 0 to 4 Hours Post Dose</title>
          <description>The diastolic and systolic blood pressure of the participants was measured. The maximum and minimum observed values from the time of the morning dose on Day 10 to 4 hours post dose were measured for SBP and DBP. The weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. Weighted mean was calculated by using all values of DBP and SBP at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
          <population>PK/PD Population</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="8.16"/>
                    <measurement group_id="O2" value="66.2" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" spread="6.66"/>
                    <measurement group_id="O2" value="62.6" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="8.14"/>
                    <measurement group_id="O2" value="71.2" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean DBP, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="7.85"/>
                    <measurement group_id="O2" value="72.2" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean DBP, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="5.69"/>
                    <measurement group_id="O2" value="68.8" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean DBP, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="8.18"/>
                    <measurement group_id="O2" value="77.0" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.0" spread="14.26"/>
                    <measurement group_id="O2" value="129.3" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.9" spread="8.25"/>
                    <measurement group_id="O2" value="122.1" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.1" spread="13.29"/>
                    <measurement group_id="O2" value="139.1" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean SBP, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.8" spread="11.78"/>
                    <measurement group_id="O2" value="120.3" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean SBP, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.9" spread="7.97"/>
                    <measurement group_id="O2" value="114.6" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean SBP, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.9" spread="11.44"/>
                    <measurement group_id="O2" value="128.2" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum and Weighted Mean Over 0 to 4 Hours Post Dose of the QT Interval Corrected According to Bazett’s Formula (QTc[B]) and the QT Interval Corrected According to Fridericia’s Formula (QTc[F])</title>
        <description>The electrocardiogram (ECG) of the participants was taken, and the maximum and weighted mean of QTc(B) and QTc(F) was measured. Weighted mean was calculated by using all values of QTc(B) and QTc(F) at the indicated timepoint contributing to the calculation of the mean but with different weightage. The ECG helps in the assessment of the condition of the heart. The QT interval gives the measure of the heart rate, and the cQT interval gives the corrected value.</description>
        <time_frame>At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 3 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum and Weighted Mean Over 0 to 4 Hours Post Dose of the QT Interval Corrected According to Bazett’s Formula (QTc[B]) and the QT Interval Corrected According to Fridericia’s Formula (QTc[F])</title>
          <description>The electrocardiogram (ECG) of the participants was taken, and the maximum and weighted mean of QTc(B) and QTc(F) was measured. Weighted mean was calculated by using all values of QTc(B) and QTc(F) at the indicated timepoint contributing to the calculation of the mean but with different weightage. The ECG helps in the assessment of the condition of the heart. The QT interval gives the measure of the heart rate, and the cQT interval gives the corrected value.</description>
          <population>PK/PD Population</population>
          <units>Milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Max, QTc(B) interval, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.0" spread="22.49"/>
                    <measurement group_id="O2" value="434.4" spread="25.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max, QTc(B) interval, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423.7" spread="18.22"/>
                    <measurement group_id="O2" value="424.7" spread="19.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max, QTc(B) interval, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.1" spread="20.29"/>
                    <measurement group_id="O2" value="447.6" spread="26.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(B), Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.8" spread="23.24"/>
                    <measurement group_id="O2" value="416.8" spread="24.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(B), Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.7" spread="18.61"/>
                    <measurement group_id="O2" value="406.3" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(B), COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.9" spread="20.48"/>
                    <measurement group_id="O2" value="431.3" spread="21.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max QTc(F), Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.5" spread="19.31"/>
                    <measurement group_id="O2" value="422.6" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max QTc(F), Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.5" spread="15.01"/>
                    <measurement group_id="O2" value="413.7" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max QTc(F), COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.9" spread="17.83"/>
                    <measurement group_id="O2" value="434.9" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(F), Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.3" spread="19.34"/>
                    <measurement group_id="O2" value="410.1" spread="20.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(F), Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.2" spread="15.03"/>
                    <measurement group_id="O2" value="401.3" spread="17.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean QTc(F), COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.9" spread="17.63"/>
                    <measurement group_id="O2" value="422.3" spread="18.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean Over 0 to 4 Hours Post Dose of Plasma Potassium and Minimum (Min) Plasma Potassium</title>
        <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the minimum plasma potassium level. Weighted mean was calculated by using all values of plasma potassium at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
        <time_frame>At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean Over 0 to 4 Hours Post Dose of Plasma Potassium and Minimum (Min) Plasma Potassium</title>
          <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the minimum plasma potassium level. Weighted mean was calculated by using all values of plasma potassium at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
          <population>Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weighted mean, Asthma + COPD; n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.209"/>
                    <measurement group_id="O2" value="4.11" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean, Asthma; n=32, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.216"/>
                    <measurement group_id="O2" value="4.10" spread="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.204"/>
                    <measurement group_id="O2" value="4.13" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Min, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="0.231"/>
                    <measurement group_id="O2" value="3.90" spread="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Min, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="0.241"/>
                    <measurement group_id="O2" value="3.89" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Min, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="0.220"/>
                    <measurement group_id="O2" value="3.92" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean Over 0 to 4 Hours Post Dose and Maximum Plasma Glucose</title>
        <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the maximum plasma glucose level. Weighted mean was calculated by using all values of plasma glucose at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
        <time_frame>At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>PK/PD Population</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean Over 0 to 4 Hours Post Dose and Maximum Plasma Glucose</title>
          <description>Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the maximum plasma glucose level. Weighted mean was calculated by using all values of plasma glucose at the indicated timepoint contributing to the calculation of the mean but with different weightage.</description>
          <population>PK/PD Population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weighted mean, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="1.119"/>
                    <measurement group_id="O2" value="5.95" spread="0.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="0.622"/>
                    <measurement group_id="O2" value="5.80" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted mean, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="1.545"/>
                    <measurement group_id="O2" value="6.16" spread="1.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max, Asthma + COPD; n=57, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="1.644"/>
                    <measurement group_id="O2" value="7.19" spread="1.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="1.147"/>
                    <measurement group_id="O2" value="6.96" spread="1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="2.105"/>
                    <measurement group_id="O2" value="7.50" spread="2.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell (WBC) Count</title>
        <description>Blood samples of participants were collected for the evaluation of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and WBC count. Data are reported for the first (1st) and second (2nd) administration (admin) of FP/salmeterol via MDPI or capsule-based inhaler. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population: all participants who received at least one dose of study medication. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell (WBC) Count</title>
          <description>Blood samples of participants were collected for the evaluation of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and WBC count. Data are reported for the first (1st) and second (2nd) administration (admin) of FP/salmeterol via MDPI or capsule-based inhaler. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population: all participants who received at least one dose of study medication. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Giga (10^9) cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.051"/>
                    <measurement group_id="O2" value="0.06" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.050"/>
                    <measurement group_id="O2" value="0.04" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.085"/>
                    <measurement group_id="O2" value="0.04" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.050"/>
                    <measurement group_id="O2" value="0.04" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.238"/>
                    <measurement group_id="O2" value="0.33" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.182"/>
                    <measurement group_id="O2" value="0.31" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.169"/>
                    <measurement group_id="O2" value="0.23" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.169"/>
                    <measurement group_id="O2" value="0.26" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.497"/>
                    <measurement group_id="O2" value="1.92" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 2nd admin, Asthma; n=31,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.461"/>
                    <measurement group_id="O2" value="1.86" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.419"/>
                    <measurement group_id="O2" value="1.72" spread="0.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.475"/>
                    <measurement group_id="O2" value="1.68" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.162"/>
                    <measurement group_id="O2" value="0.55" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.133"/>
                    <measurement group_id="O2" value="0.52" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.161"/>
                    <measurement group_id="O2" value="0.60" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.157"/>
                    <measurement group_id="O2" value="0.63" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.097"/>
                    <measurement group_id="O2" value="3.37" spread="1.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="0.904"/>
                    <measurement group_id="O2" value="3.28" spread="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="1.601"/>
                    <measurement group_id="O2" value="3.48" spread="1.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="1.060"/>
                    <measurement group_id="O2" value="3.75" spread="1.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.1" spread="40.05"/>
                    <measurement group_id="O2" value="223.9" spread="41.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.7" spread="43.08"/>
                    <measurement group_id="O2" value="230.8" spread="49.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, 1st admin, COPD; n=24, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.6" spread="50.56"/>
                    <measurement group_id="O2" value="226.6" spread="52.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, 2nd admin, COPD; n=23, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.1" spread="52.73"/>
                    <measurement group_id="O2" value="240.1" spread="48.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.145" spread="1.3253"/>
                    <measurement group_id="O2" value="6.182" spread="1.3646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.071" spread="1.1892"/>
                    <measurement group_id="O2" value="5.976" spread="1.3528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.340" spread="1.9346"/>
                    <measurement group_id="O2" value="6.036" spread="1.3076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.092" spread="1.2752"/>
                    <measurement group_id="O2" value="6.312" spread="1.8600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hemoglobin and Mean Corpuscular Hemoglobin (MCH) Concentration</title>
        <description>Blood samples of participants were collected for the evaluation of mean hemoglobin (mean level of hemoglobin in the whole blood sample) and MCH concentration. The MCH concentration is the average concentration of hemoglobin in a red blood cell. Hemoglobin is the red pigment in the blood, and it is reponsible for carrying oxygen. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin and Mean Corpuscular Hemoglobin (MCH) Concentration</title>
          <description>Blood samples of participants were collected for the evaluation of mean hemoglobin (mean level of hemoglobin in the whole blood sample) and MCH concentration. The MCH concentration is the average concentration of hemoglobin in a red blood cell. Hemoglobin is the red pigment in the blood, and it is reponsible for carrying oxygen. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="12.20"/>
                    <measurement group_id="O2" value="135.4" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.0" spread="14.31"/>
                    <measurement group_id="O2" value="132.3" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="12.07"/>
                    <measurement group_id="O2" value="133.1" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.6" spread="14.65"/>
                    <measurement group_id="O2" value="128.5" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH concentration, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.7" spread="9.85"/>
                    <measurement group_id="O2" value="334.0" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH concentration, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.0" spread="11.21"/>
                    <measurement group_id="O2" value="333.2" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH concentration, 1st admin, COPD; n=,25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.0" spread="9.69"/>
                    <measurement group_id="O2" value="328.5" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH concentration, 1st admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.4" spread="11.47"/>
                    <measurement group_id="O2" value="328.8" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cell (RBC) Count and Reticulocytes</title>
        <description>Blood samples of participants were collected for the evaluation of RBC and reticulocytes count. Reticulocytes are immature red blood cells. Normally, about 1% to 2% of the red blood cells in the blood are reticulocytes. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell (RBC) Count and Reticulocytes</title>
          <description>Blood samples of participants were collected for the evaluation of RBC and reticulocytes count. Reticulocytes are immature red blood cells. Normally, about 1% to 2% of the red blood cells in the blood are reticulocytes. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Trillion (10^12) cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.608" spread="0.3590"/>
                    <measurement group_id="O2" value="4.542" spread="0.3616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.460" spread="0.4059"/>
                    <measurement group_id="O2" value="4.424" spread="0.3638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, 1st admin, Asthma, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.523" spread="0.5483"/>
                    <measurement group_id="O2" value="4.530" spread="0.5906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.438" spread="0.6062"/>
                    <measurement group_id="O2" value="4.358" spread="0.6342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, 1st admin, Asthma ; n=33, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.0178"/>
                    <measurement group_id="O2" value="0.050" spread="0.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.0195"/>
                    <measurement group_id="O2" value="0.050" spread="0.0193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.0191"/>
                    <measurement group_id="O2" value="0.054" spread="0.0230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, 2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" spread="0.0252"/>
                    <measurement group_id="O2" value="0.061" spread="0.0271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscule Hemoglobin (MCH)</title>
        <description>Blood samples of participants were collected for the evaluation of MCH. MCH is the average mass or amount of hemoglobin per red blood cell in a sample of blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subject Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscule Hemoglobin (MCH)</title>
          <description>Blood samples of participants were collected for the evaluation of MCH. MCH is the average mass or amount of hemoglobin per red blood cell in a sample of blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subject Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>picograms (pg)/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.99" spread="1.422"/>
                    <measurement group_id="O2" value="29.86" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.80" spread="1.501"/>
                    <measurement group_id="O2" value="29.92" spread="1.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.72" spread="2.920"/>
                    <measurement group_id="O2" value="29.72" spread="2.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.73" spread="3.079"/>
                    <measurement group_id="O2" value="29.83" spread="2.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscle Volume (MCV)</title>
        <description>Blood samples of participants were collected for the evaluation of MCV. MCV is a measure of the average red blood cell size that is reported as part of a standard complete blood count. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscle Volume (MCV)</title>
          <description>Blood samples of participants were collected for the evaluation of MCV. MCV is a measure of the average red blood cell size that is reported as part of a standard complete blood count. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Femtoliters (fL; 10^-15 L)/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.65" spread="2.808"/>
                    <measurement group_id="O2" value="89.41" spread="2.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.52" spread="2.953"/>
                    <measurement group_id="O2" value="89.77" spread="2.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.21" spread="7.643"/>
                    <measurement group_id="O2" value="90.37" spread="7.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.76" spread="7.609"/>
                    <measurement group_id="O2" value="90.64" spread="7.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hematocrit</title>
        <description>Blood samples of participants were collected for the evaluation of hematocrit. The hematocrit is the percentage of the RBCs in the blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematocrit</title>
          <description>Blood samples of participants were collected for the evaluation of hematocrit. The hematocrit is the percentage of the RBCs in the blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>percentage of RBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.413" spread="0.0318"/>
                    <measurement group_id="O2" value="0.405" spread="0.0328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.399" spread="0.0375"/>
                    <measurement group_id="O2" value="0.396" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.405" spread="0.0346"/>
                    <measurement group_id="O2" value="0.405" spread="0.0379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, COPD; n=24, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.400" spread="0.0448"/>
                    <measurement group_id="O2" value="0.391" spread="0.0441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Albumin and Total Protein</title>
        <description>The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Albumin and Total Protein</title>
          <description>The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="2.47"/>
                    <measurement group_id="O2" value="42.3" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="2.02"/>
                    <measurement group_id="O2" value="41.8" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="2.19"/>
                    <measurement group_id="O2" value="41.4" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="2.30"/>
                    <measurement group_id="O2" value="40.0" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="4.29"/>
                    <measurement group_id="O2" value="66.0" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="3.48"/>
                    <measurement group_id="O2" value="64.8" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="3.82"/>
                    <measurement group_id="O2" value="64.9" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="4.01"/>
                    <measurement group_id="O2" value="63.5" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST), and Gama Glutamyl Transferase (GGT)</title>
        <description>Blood samples of participants were collected for the evaluation of AP, ALT, AST, and GGT. All of these parameters are measured to help assess the condition of the liver. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST), and Gama Glutamyl Transferase (GGT)</title>
          <description>Blood samples of participants were collected for the evaluation of AP, ALT, AST, and GGT. All of these parameters are measured to help assess the condition of the liver. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AP, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="15.00"/>
                    <measurement group_id="O2" value="63.4" spread="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="14.87"/>
                    <measurement group_id="O2" value="63.9" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, 1st admin, COP ; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="20.28"/>
                    <measurement group_id="O2" value="69.9" spread="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="18.31"/>
                    <measurement group_id="O2" value="68.4" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="9.49"/>
                    <measurement group_id="O2" value="20.4" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="11.32"/>
                    <measurement group_id="O2" value="19.1" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="10.47"/>
                    <measurement group_id="O2" value="23.4" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="10.80"/>
                    <measurement group_id="O2" value="21.2" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="8.22"/>
                    <measurement group_id="O2" value="21.6" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="5.85"/>
                    <measurement group_id="O2" value="20.1" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="7.44"/>
                    <measurement group_id="O2" value="24.7" spread="14.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="8.95"/>
                    <measurement group_id="O2" value="21.1" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="14.51"/>
                    <measurement group_id="O2" value="21.0" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="19.22"/>
                    <measurement group_id="O2" value="21.0" spread="15.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="53.90"/>
                    <measurement group_id="O2" value="44.0" spread="80.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="32.85"/>
                    <measurement group_id="O2" value="29.6" spread="24.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Direct Bilirubin (DB), Total Bilirubin (TB), Creatinine, and Uric Acid</title>
        <description>Blood samples of participants were collected for the evaluation of DP, TB, creatinine, and uric acid. DB and TB are measures that help assess the condition of the liver, and creatinine and uric acid are measures that help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Direct Bilirubin (DB), Total Bilirubin (TB), Creatinine, and Uric Acid</title>
          <description>Blood samples of participants were collected for the evaluation of DP, TB, creatinine, and uric acid. DB and TB are measures that help assess the condition of the liver, and creatinine and uric acid are measures that help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>Micromoles per liter (µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DB, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.83"/>
                    <measurement group_id="O2" value="2.7" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.47"/>
                    <measurement group_id="O2" value="2.6" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.97"/>
                    <measurement group_id="O2" value="2.8" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.16"/>
                    <measurement group_id="O2" value="2.9" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="3.58"/>
                    <measurement group_id="O2" value="9.9" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="4.48"/>
                    <measurement group_id="O2" value="8.6" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="2.42"/>
                    <measurement group_id="O2" value="9.4" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TB, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.76"/>
                    <measurement group_id="O2" value="8.4" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="11.48"/>
                    <measurement group_id="O2" value="75.8" spread="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="10.81"/>
                    <measurement group_id="O2" value="75.2" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4" spread="18.33"/>
                    <measurement group_id="O2" value="77.7" spread="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="17.38"/>
                    <measurement group_id="O2" value="79.4" spread="18.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 1st admin, Asthma n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.9" spread="73.11"/>
                    <measurement group_id="O2" value="331.5" spread="66.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.4" spread="67.25"/>
                    <measurement group_id="O2" value="325.6" spread="70.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.2" spread="60.13"/>
                    <measurement group_id="O2" value="348.3" spread="59.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.7" spread="65.96"/>
                    <measurement group_id="O2" value="352.0" spread="64.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Calcium, Chloride, Glucose, Potassium, Sodium, Carbon Dioxide (CO2) Content/Bicarbonate (Bicar), and Urea/Blood Urea Nitrogen (BUN)</title>
        <description>Blood samples of participants were collected for the evaluation of calcium, chloride, glucose, potassium, sodium, carbon dioxide (CO2) content/bicarbonate, and urea/BUN. All of these parameters are measured to help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
        <time_frame>Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Calcium, Chloride, Glucose, Potassium, Sodium, Carbon Dioxide (CO2) Content/Bicarbonate (Bicar), and Urea/Blood Urea Nitrogen (BUN)</title>
          <description>Blood samples of participants were collected for the evaluation of calcium, chloride, glucose, potassium, sodium, carbon dioxide (CO2) content/bicarbonate, and urea/BUN. All of these parameters are measured to help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was &quot;ABBA,&quot; then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, 1st admin, Asthma; n=33, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.191" spread="0.0954"/>
                    <measurement group_id="O2" value="2.178" spread="0.0900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.190" spread="0.0799"/>
                    <measurement group_id="O2" value="2.170" spread="0.1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.205" spread="0.0874"/>
                    <measurement group_id="O2" value="2.189" spread="0.0946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.206" spread="0.0998"/>
                    <measurement group_id="O2" value="2.190" spread="0.0916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" spread="2.38"/>
                    <measurement group_id="O2" value="104.8" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.5" spread="2.29"/>
                    <measurement group_id="O2" value="105.3" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 1st admin, COP; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.4" spread="2.80"/>
                    <measurement group_id="O2" value="104.0" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 2nd admin, COPD n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="2.49"/>
                    <measurement group_id="O2" value="104.4" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="0.555"/>
                    <measurement group_id="O2" value="5.06" spread="0.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="0.325"/>
                    <measurement group_id="O2" value="5.15" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="0.846"/>
                    <measurement group_id="O2" value="5.37" spread="1.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.63" spread="1.143"/>
                    <measurement group_id="O2" value="5.45" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 1st admin, Asthma; n=32, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="0.421"/>
                    <measurement group_id="O2" value="4.05" spread="0.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="0.291"/>
                    <measurement group_id="O2" value="4.02" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 1st admin, COPD n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="0.212"/>
                    <measurement group_id="O2" value="4.08" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="0.223"/>
                    <measurement group_id="O2" value="4.11" spread="0.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.5" spread="1.80"/>
                    <measurement group_id="O2" value="140.5" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.1" spread="2.13"/>
                    <measurement group_id="O2" value="140.4" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 1st admin, COPD n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.5" spread="2.69"/>
                    <measurement group_id="O2" value="140.5" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 2nd admin, COPD n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.1" spread="2.49"/>
                    <measurement group_id="O2" value="140.2" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/bicar, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="2.09"/>
                    <measurement group_id="O2" value="25.6" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/bicar, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="2.22"/>
                    <measurement group_id="O2" value="26.0" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/bicar, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="1.90"/>
                    <measurement group_id="O2" value="27.3" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/bicar, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="2.08"/>
                    <measurement group_id="O2" value="27.2" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 1st admin, Asthma; n=33, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="1.389"/>
                    <measurement group_id="O2" value="5.41" spread="1.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread="1.290"/>
                    <measurement group_id="O2" value="5.43" spread="1.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 1st admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="1.426"/>
                    <measurement group_id="O2" value="6.09" spread="1.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.90" spread="1.402"/>
                    <measurement group_id="O2" value="6.12" spread="1.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Adverse Event (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Randomization (Day 1) up to Follow-up (Days 47-50)</time_frame>
        <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP/Salmeterol From MDPI</title>
            <description>Fluticasone propionate (FP)/salmeterol combination was administered as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for two 10-day periods</description>
          </group>
          <group group_id="O2">
            <title>FP/Salmeterol From Capsule-based Inhaler</title>
            <description>Fluticasone propionate/salmeterol combination was administered as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for two 10-day periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <population>All Subjects Population. Out of the total population, 34 participants had asthma and 26 participants had COPD. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st admin, Asthma; n=33, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, Asthma; n=31, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st admin, COPD; n=26, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd admin, COPD; n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FP/Salmeterol From MDPI 1st Administration (Admin), Asthma</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with asthma as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for a 10-day period.</description>
        </group>
        <group group_id="E2">
          <title>FP/Salmeterol From MDPI 2nd Admin, Asthma</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to particiapants with asthma as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for a 10-day period.</description>
        </group>
        <group group_id="E3">
          <title>FP/Salmeterol From Capsule-based Inhaler 1st Admin, Asthma</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with asthma as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for a 10-day period.</description>
        </group>
        <group group_id="E4">
          <title>FP/Salmeterol From Capsule-based Inhaler 2nd Admin, Asthma</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with asthma as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for a 10-day period.</description>
        </group>
        <group group_id="E5">
          <title>FP/Salmeterol From MDPI 1st Admin, COPD</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with COPD as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for a 10-day period.</description>
        </group>
        <group group_id="E6">
          <title>FP/Salmeterol From MDPI 2nd Admin, COPD</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with COPD as a powder in blister in the dose of 250/50 micrograms (mcg) twice daily (BID) via a multi-dose dry powder inhaler (MDPI) for a 10-day period.</description>
        </group>
        <group group_id="E7">
          <title>FP/Salmeterol From Capsule-based Inhaler 1st Admin, COPD</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with COPD as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for a 10-day period.</description>
        </group>
        <group group_id="E8">
          <title>FP/Salmeterol From Capsule-based Inhaler 2nd Admin, COPD</title>
          <description>Fluticasone propionate (FP)/salmeterol combination was administered to participants with COPD as a powder in capsule in the dose of 250/50 mcg BID via a capsule-based inhaler for a 10-day period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

